About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Medicus Pharma Ltd

News headline image
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma To Participate in the 38th Annual Roth Conference
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
News headline image
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
From Medicus Pharma Ltd
Via GlobeNewswire
Tickers MDCX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.